MSTN and Duchenne muscular dystrophy: This study aimed to address whether an oral administration of BLS-M22 could elicit sufficient levels of myostatin-specific antibodies and whether the generation of the antibodies could improve the dystrophic features of an animal model of DMD (mdx model).